ReviewExpert opinion on therapeutic patents2012
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.
Review in Expert opinion on therapeutic patents, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 94 citations in OpenAlex.
- Broccoli Cultivated with Deep Sea Water Mineral Fertilizer Enhances Anti-Cancer and Anti-Inflammatory Effects of AOM/DSS-Induced Colorectal Cancer in C57BL/6N Mice.International journal of molecular sciences · 2024Article
- Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors.International journal of molecular sciences · 2023Article
- Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.Expert opinion on therapeutic patents · 2022Review
- Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody.Cancers · 2020Article
- Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein.Frontiers in chemistry · 2020Article
- Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies.Nature communications · 2019Article
- Alveolar Macrophage Apoptosis-associated Bacterial Killing Helps Prevent Murine Pneumonia.American journal of respiratory and critical care medicine · 2019Article
- Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening.Scientific reports · 2018Article
- miR-371-5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2.Oncology letters · 2018Article
- Genes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions.Molecular medicine reports · 2018Article
- miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.Genes & development · 2017Article
- Article
- Treatment of Elderly Patients With Acute Myeloid Leukemia.Current treatment options in oncology · 2017Review
- DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.Journal of medicinal chemistry · 2016Article
- Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.Journal of experimental & clinical cancer research : CR · 2015Article
- New dimension in therapeutic targeting of BCL-2 family proteins.Oncotarget · 2015Review
- IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.The Journal of allergy and clinical immunology · 2015Article
- Small molecule Mcl-1 inhibitors for the treatment of cancer.Pharmacology & therapeutics · 2015Review
- 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.Journal of medicinal chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe B-cell lymphoma-2 (Bcl-2) family of proteins is central to the regulation of apoptosis, which is vital for proper tissue development and cellular homeostasis. Anti-apoptotic proteins, members of the Bcl-2 family, are an important survival factor for many cancers and their overexpression has been associated with tumor initiation, progression, and resistance to current anticancer therapies. Therefore, strategies seeking to antagonize the function of Bcl-2 anti-apoptotic proteins have been extensively studied for developing a novel cancer therapy. AREAS COVERED: This review covers research and patent literature of the last 15 years dealing with the discovery and development of inhibitors of the Bcl-2 protein family. EXPERT OPINION: The feasibility of disrupting protein-protein interactions between anti-apoptotic and pro-apoptotic proteins, members of the Bcl-2 family, using peptidomimetics and small-molecule inhibitors has been successfully established. Three small-molecule inhibitors have entered human clinical trials, which will allow the evaluation of this potential therapeutic approach in cancer patients. It will be important to gain a better understanding of pan and selective Bcl-2 inhibitors in order to facilitate future drug design efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.